GLP-1/glucagon receptor co-agonism for treatment of obesity

Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

Research output: Contribution to journalReview articlepeer-review

130 Scopus citations


Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.

Original languageEnglish
Pages (from-to)1851-1861
Number of pages11
Issue number10
StatePublished - 1 Oct 2017


  • Co-agonism
  • Dual agonism
  • GLP-1
  • Glucagon
  • Multi-agonist
  • Obesity
  • Pharmacology
  • Review
  • Translational
  • Type 2 diabetes


Dive into the research topics of 'GLP-1/glucagon receptor co-agonism for treatment of obesity'. Together they form a unique fingerprint.

Cite this